Polyrizon (PLRZ) Competitors $1.12 -0.05 (-4.27%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLRZ vs. LPTX, LNAI, CVKD, ENLV, PMN, PASG, MIRA, ALLR, MBRX, and CASIShould you be buying Polyrizon stock or one of its competitors? The main competitors of Polyrizon include Leap Therapeutics (LPTX), Lunai Bioworks (LNAI), Cadrenal Therapeutics (CVKD), Enlivex Therapeutics (ENLV), Promis Neurosciences (PMN), Passage Bio (PASG), MIRA Pharmaceuticals (MIRA), Allarity Therapeutics (ALLR), Moleculin Biotech (MBRX), and CASI Pharmaceuticals (CASI). These companies are all part of the "pharmaceutical products" industry. Polyrizon vs. Its Competitors Leap Therapeutics Lunai Bioworks Cadrenal Therapeutics Enlivex Therapeutics Promis Neurosciences Passage Bio MIRA Pharmaceuticals Allarity Therapeutics Moleculin Biotech CASI Pharmaceuticals Polyrizon (NASDAQ:PLRZ) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends. Do institutionals and insiders believe in PLRZ or LPTX? 30.5% of Leap Therapeutics shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend PLRZ or LPTX? Leap Therapeutics has a consensus target price of $3.38, indicating a potential upside of 440.87%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Polyrizon.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Leap Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Is PLRZ or LPTX more profitable? Polyrizon's return on equity of 0.00% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets PolyrizonN/A N/A N/A Leap Therapeutics N/A -237.65%-155.38% Does the media favor PLRZ or LPTX? In the previous week, Leap Therapeutics had 1 more articles in the media than Polyrizon. MarketBeat recorded 4 mentions for Leap Therapeutics and 3 mentions for Polyrizon. Leap Therapeutics' average media sentiment score of 0.73 beat Polyrizon's score of 0.63 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Polyrizon 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Leap Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, PLRZ or LPTX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPolyrizonN/AN/A-$1.54MN/AN/ALeap TherapeuticsN/AN/A-$67.56M-$1.58-0.39 SummaryLeap Therapeutics beats Polyrizon on 6 of the 9 factors compared between the two stocks. Get Polyrizon News Delivered to You Automatically Sign up to receive the latest news and ratings for PLRZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLRZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLRZ vs. The Competition Export to ExcelMetricPolyrizonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.71M$3.40B$6.05B$10.51BDividend YieldN/A2.30%5.73%4.80%P/E RatioN/A22.9285.3627.35Price / SalesN/A268.92516.10196.40Price / CashN/A46.9537.5761.53Price / Book0.0010.5512.426.82Net Income-$1.54M-$52.58M$3.32B$276.80M7 Day Performance-6.67%1.09%0.97%0.26%1 Month Performance-5.08%16.09%10.70%8.29%1 Year PerformanceN/A18.41%76.19%35.59% Polyrizon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLRZPolyrizonN/A$1.12-4.3%N/AN/A$6.71MN/A0.00N/AGap UpLPTXLeap Therapeutics2.6212 of 5 stars$0.69-7.6%$3.38+387.0%-73.5%$29.22MN/A-0.4540LNAILunai BioworksN/A$1.24flatN/AN/A$28.74MN/A-0.1620Positive NewsCVKDCadrenal Therapeutics2.2994 of 5 stars$14.00+0.3%$32.00+128.6%-2.8%$28.66MN/A-1.584ENLVEnlivex Therapeutics2.8581 of 5 stars$1.18+0.4%$10.00+751.1%-23.4%$28.54MN/A-2.0370PMNPromis Neurosciences3.4787 of 5 stars$0.53-7.7%$4.33+723.8%-54.1%$28.36MN/A-2.515Positive NewsGap UpPASGPassage Bio3.6223 of 5 stars$8.75+5.6%$75.67+765.3%-29.2%$27.81MN/A-0.48130News CoverageGap UpMIRAMIRA Pharmaceuticals1.162 of 5 stars$1.35+1.9%N/A+22.4%$25.65MN/A-2.742ALLRAllarity Therapeutics2.766 of 5 stars$1.75+2.9%$9.25+428.6%+6.3%$25.56MN/A0.0010MBRXMoleculin Biotech2.7793 of 5 stars$0.51+1.0%$4.00+679.7%-79.1%$25.29MN/A0.0020CASICASI Pharmaceuticals3.9167 of 5 stars$2.04+0.2%$4.00+96.6%-68.9%$25.03M$31.56M-0.70180Analyst Forecast Related Companies and Tools Related Companies Leap Therapeutics Alternatives Lunai Bioworks Alternatives Cadrenal Therapeutics Alternatives Enlivex Therapeutics Alternatives Promis Neurosciences Alternatives Passage Bio Alternatives MIRA Pharmaceuticals Alternatives Allarity Therapeutics Alternatives Moleculin Biotech Alternatives CASI Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLRZ) was last updated on 10/15/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Polyrizon Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Polyrizon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
